BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

Preclinical publications highlighted in BioCentury’s Distillery this year identified white space target opportunities including untapped E3 ubiquitin ligases, vesicular regulators and ion channels, as...
BioCentury | Jun 26, 2020
Distillery Therapeutics

FMR1 peptide therapy for Fragile X syndrome

...and anxiety behaviors; and countered disease-associated elevations in APP and CAMK2A and disease-associated reductions in PSD95...
...FMR1; FMRP); amyloid precursor protein (APP); calcium calmodulin-dependent protein kinase II alpha (CAMK2A); discs large homolog 4 (PSD95; DLG4...
BioCentury | Jun 26, 2020
Distillery Therapeutics

Promoting Golgi fragmentation to treat pancreatic cancer

DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer Inducing Golgi complex fragmentation by inhibiting the transcription factor KLF7 or the Golgi integrity maintenance factors DLG3 or STX5 could treat pancreatic ductal adenocarcinoma (PDAC). In pancreas samples from...
BioCentury | Mar 7, 2020
Product Development

If NoNO’s stroke trial strategy pays off, it could bring the first new therapy in a generation

...PSD95, and between PSD95 and NO synthase, disrupting NO production while sparing normal physiological signaling. PSD95...
...normal physiological signaling. PSD95 (DLG4) - Discs large homolog 4 A novel mechanism and model Tymianski believes targeting PSD95...
...to try to develop neuroprotectants.” Targets ND2 - NADH dehydrogenase subunit 2 PSD95 (DLG4) - Discs large homolog 4...
BioCentury | Feb 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: January 2018

New Therapeutic Targets and Biomarkers: January 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during January 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Jan 31, 2018
Distillery Therapeutics

Neurology

INDICATION: Stroke Patient sample and mouse studies suggest inhibiting miR-143 or promoting expression of its inhibitor DLGAP4’s circular RNA (circRNA) could help treat stroke. In serum samples from patients, levels of miR-143 were higher and...
BioCentury | May 24, 2017
Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling A panel of oncogenic gene fusions in tumors could provide new therapeutic targets for colorectal cancer. Transcriptome sequencing of stage I-III primary tumors and matched healthy colon tissue from 278 colorectal cancer...
BioCentury | Mar 3, 2017
Clinical News

NA-1: Ph III ESCAPE-NA-1 started

...NoNo Inc. , Toronto, Ontario Product: NA-1 Business: Neurology Molecular target: Discs large homolog 4 ( PSD95 ; DLG4...
...and mRS and mortality rate over 90 days Status: Phase III started Milestone: NA Julian Zhu NoNO Inc. Discs large homolog 4 (PSD95) (DLG4) MicroRNA-100...
BioCentury | Mar 3, 2016
Targets & Mechanisms

Rescue mission

...that stabilizes actin filaments and several proteins, including NMDA receptors, mGluRs and the postsynaptic scaffold PSD95...
...of rapamycin PPP2CA ( PP2A ) - Protein phosphatase 2 PSD95 ( DLG4 ) - Discs large homolog 4...
...PPP2CA ( PP2A ) - Protein phosphatase 2 ; PSD95 ( DLG4 ) - Discs large homolog 4...
BioCentury | Jan 20, 2014
Emerging Company Profile

Zocere: Stepping up in stroke

...NMDA pathway. NoNO Inc. 's NA-1 is a peptide that inhibits discs large homolog 4 ( DLG4 ; PSD95...
Items per page:
1 - 10 of 20